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Abstract
We have investigated the mechanistic basis of our recent observation that exposing young mice to an industrial surfactant
potentiates the inhibition of fatty-acid b-oxidation that occurs with subsequent virus infection Murphy et al., Biochim.
.  .Biophys. Acta 1315, 208–216, 1996 . In our mouse model for acute hepatic encephalopathy AHE , neonatal mice were
painted on their abdomens from birth to postnatal day 12 with nontoxic amounts of the industrial surfactant, Toximul MP8
 .  .  .  .Tox , and then infected with a sublethal dose LD of mouse-adapted human Influenza B Lee virus FluB . Mortality in30
mice treated with ToxqFluB was significantly higher than that in mice treated with FluB alone. In vitro assays of hepatic
w 14 x w 14 x  .b-oxidation of 1- C palmitic and 1- C octanoic acids in the presence or absence of exogenous coenzyme A CoA
indicated that Tox-mediated inhibition of oxidation was masked when CoA was added to the assays. FluB also inhibited
b-oxidation by 20–30%, however this effect was independent of exogenous CoA which suggested that it involved a
 .different mechanism. Tox-mediated potentiation of the inhibitory effect was most obvious )80% inhibition when assays
were done without added CoA. Analysis of hepatic CoA and its esters indicated that levels of both free CoA and
acetyl-CoA were significantly lower in mice that were painted with Tox for 12 days. Tox-dependent reductions of
acetyl-CoA were transient and returned to normal values after cessation of painting, whereas those of CoA persisted. FluB
 .infection alone significantly reduced hepatic acetyl-CoA and the magnitude of this reduction )30% was not affected by
pre-exposing the mice to Tox. Relative to control mice, levels of acid insoluble acyl-CoA esters were elevated significantly
w 14 x w 14 xin FluB and ToxqFluB treated mice. Activation of both 1- C palmitic and 1- C octanoic acids was reduced in
Tox-exposed mice at experimental day 12, but only when exogenous CoA was not included in the assay media; this effect
appeared to persist after cessation of painting. Collectively, these data support the concept that Tox and FluB have
independent effects on hepatic CoA metabolism that are associated with abnormalities in fatty-acid b-oxidation. However,
 .Abbreviations: AHE, acute hepatic encephalopathy; Tox, Toximul MP8; FluB, mouse-adapted human influenza B Lee virus; RS,
 .Reye’s Syndrome; CoA, coenzyme A; MEM, minimal essential medium; PCA, perchloric acid; WSP, water-soluble product s ; BSA,
bovine serum albumin.
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these do not fully explain the synergistic effect of the virus and chemical on b-oxidation inhibition, which is a candidate
co-mechanism for potentiation of mortality in this mouse model of AHE.
Keywords: Acute hepatic encephalopathy; Surfactantrvirus mouse model; Hepatic fatty acid b-oxidation; Coenzyme A metabolism;
Reye’s Syndrome; Fatty acid activation
1. Introduction
Disturbances in hepatic fatty-acid b-oxidation are
being described more frequently with clinical toxicity
in association with an increasing number of struc-
turally-diverse xenobiotic chemicals for review, see
w x.1,2 , including therapeutic agents such as salicylates
w x w x w x3,4 , antibiotics 5 , valproic acid 6 , and known
w xtoxins such as 3-mercaptopropionic acid 7 and hy-
w xpoglycin 8 . These appear to function by a variety of
different mechanisms, but the resulting inhibition of
this crucial pathway in intermediary metabolism re-
sults in hepatotoxicity leading often to coma and
death.
For many years we have used a surfactantrvirus
 .mouse model to study Reye’s Syndrome RS , a
frequently-cited example of AHE. The model in-
volves painting neonatal mice with apparently non-
toxic amounts of the industrial surfactant which is
frequently used in forestry spray programs, Toximul
 .MP8 Tox , on their abdomens daily for 12 days, and
subsequently infecting them with sublethal doses
 .  .LD of mouse-adapted human influenza B Lee30
 .virus FluB . Our studies demonstrated that Toxq
FluB treatment produces many of the features of
human RS, including mitochondrial structural
changes, hyperammonemia, elevated intracranial
w xpressure and a high mortality rate 9–13 . Recently,
we reported that Tox exacerbates virus-induced inhi-
bition of fatty-acid b-oxidation in the mouse model
w x14 . These initial in vitro assays with liver ho-
mogenates from the different treatment groups con-
.trol, Tox, FluB and ToxqFluB indicated an appar-
went time-dependent increase in oxidation of 1-
14 xC palmitic acid in mice painted with Tox, inhibition
of its oxidation associated with FluB infection, and a
potentiation of the inhibitory effect in mice given
combined ToxqFluB treatment. Other than having
indirect evidence that treatment with Tox alone stim-
ulated peroxisomal oxidation, we did not investigate
the mechanisms underlying these observations, nor
did we resolve the apparent discrepancy between the
effects of Tox, FluB and ToxqFluB.
Recent reports that some of the xenobiotics could
be inhibiting b-oxidation by sequestering or deplet-
ing intracellular CoA suggested a possible explana-
tion for some of our above findings. This phe-
w xnomenon was demonstrated with valproic 15,16 and
w x w xsalicylic acid 3 , ibuprofen 17 and pivampicillin
w x18 . Each of these agents is either a carboxylic acid
or is converted into one in vivo, and subsequently
activated to a CoA thioester. As such, they have the
potential to compete with endogenous carboxylic
acids for the CoA that is necessary to undergo key
metabolic reactions, including b-oxidation. The Tox
that we use in the mouse model is a complex mixture
w xof anionic and nonionic hydrocarbons 19 , some of
which are converted by v-oxidation to carboxylic
acids in vivo, activated to acyl-CoA esters, and de-
w xgraded in the peroxisomes by b-oxidation 20 .
Therefore, we postulated that Tox also could be
sequestering hepatic CoA, and that this would ac-
count for its ability to potentiate FluB-dependent
inhibition of b-oxidation. Such an action in earlier
studies would not have been apparent, as these in
vitro experiments were carried out in the presence of
saturating quantities of all reaction cofactors, includ-
ing CoA. The purpose of the present study was to
determine how presumably nontoxic doses of Tox
and infection with FluB affect cellular CoA
metabolism, including levels of CoA and its metabo-
lites, and such processes as fatty-acid activation to
 .acyl-CoA esters by acid:CoA ligase EC 6.2.1.1-3 .
2. Materials and methods
2.1. Materials
w 14 x 1- C Palmitic acid specific activity, 56
. w 14 x mCirmmol and 1- C octanoic acid specific activ-
.ity, 53.5 mCirmmol were obtained from Dupont
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 .Canada Mississauga, Canada . Palmitic acid and
other lipid standards were from Serdary Research
 .Laboratories Inc. London, Canada . Phospho-trans-
 .acetylase PTA, EC 2.3.1.8 , acetylphosphate, citrate
synthase, ATP, L-carnitine, coenzyme A, dithio-
threitol and fatty-acid-poor bovine serum albumin
 . BSA were purchased from Sigma Chemical Co. St.
.Louis, MO, USA . Whatman glass microfibre paper
 . GFrB was from Fisher Scientific Co. Halifax,
.Canada . FluB was originally obtained from Dr. Frank
Ennis, National Institutes of Health, Bethesda, MD.
 .Toximul MP8 Tox, Lot a9-30162 was from Char-
les Tenant Co., Toronto, Canada.
2.2. SurfactantrFluB ˝irus mouse model
The surfactantrvirus mouse model for AHE has
w xbeen described in detail elsewhere 11,14 . Briefly,
male and female Swiss Webster ND4, Harlan
.Sprague Dawley, Indianapolis, IN white mice were
mated and the mothers were allowed to deliver. Mice
born on the day in which the largest number of births
occurred were pooled and were randomly divided
into groups of nine pups per nursing mother. 24 h
later, the pups were divided arbitrarily into two
 .groups; minimal essential medium MEM was ap-
plied dermally to the abdomens of the first group,
while the other group was painted with the industrial
surfactant, Tox, that was diluted in MEM 1%, by
.vol . This treatment was repeated daily for 12 days.
For the first 5 days, the mice received 8.6"2.6 mg
Toxrday; the dosage was increased to 25.8"9.0
mgrday for the last 7 days. On day 14, half of each
of the MEM and Tox groups received 10 ml of
 .  .mouse-adapted human influenza B Lee virus FluB
 .640 HA Ur0.5 ml intranasally under light ether
anaesthesia; the other half of each group received
anaesthetic alone. Deaths were recorded each morn-
ing throughout the experiment. All studies were car-
ried out in accordance with the guidelines set by the
Canadian Council on Animal Care.
2.3. Fatty-acid b-oxidation assay
At different times during the painting and post-in-
fection periods, 3 to 6 mice were taken from each
experimental group and were killed by decapitation.
The livers were excised immediately in ice-cold mod-
 .ified Krebs-Henseleit bicarbonate buffer pH 7.4 that
contained no Ca2q and 2 mM Mg2q and was gassed
 .with CO rO 95r5, vrv for at least 20 min.2 2
 .Homogenates 1–5%, wtrvol were prepared using 6
strokes of a glass-Teflon homogenizer, and were used
immediately for the assays, as b-oxidation activity is
w 14 xnot detected in frozen tissue. 1- C Palmitic acid
b-oxidation was measured essentially as described
w xpreviously 14 . The reaction mixtures contained, in a
final volume of 150 ml of modified Krebs-Henseleit
w 14 x buffer: 0.2 mM 1- C palmitic acid 4000–5000
.dpmrnmol bound to fatty-acid poor BSA in a 3:1
molar ratio, 1 mM ATP, 2 mM dithiothreitol, 0.5 mM
L-carnitine, with or without 0.05 mM CoA. The
reaction mixture was pipetted into the bottom of a 1.5
ml polypropylene tube that was placed in a 20 ml
screw-cap glass liquid scintillation vial. An 8 mm
disk of GFrB glass fibre paper that was saturated
 .with 80 ml of hyamine hydroxide 1 M in methanol
was placed on the bottom of the glass vial away from
the reaction tube. Reactions were initiated by addition
of 50 ml of liver homogenate 30–50 mg protein
when CoA was added to the mixture, or 150–160 mg
.protein when there was no exogenous CoA , and
incubations were continued for 5 min at 378C. We
had determined previously that these parameters were
optimal for the in vitro assay. Reactions were termi-
nated by the addition of 20 ml of perchloric acid
 .PCA, 70%, by vol to the assay tube, and the vials
were quickly recapped and allowed to equilibrate for
30 min. The tubes were removed from the vials, 7 ml
of scintillation fluid were added to the latter, and
radioactivity in 14CO was counted. The contents of2
the polypropylene tubes were extracted with chloro-
 .formrmethanol 2r1, volrvol , and samples of the
aqueous and organic phases were counted for mea-
 .surement of water-soluble WSP and lipid products,
respectively. Rates of b-oxidation were taken as the
sum of 14CO q4C-WSP formedrmg homogenate2
protein. Protein was determined using the method of
w xLowry et al. 21 , using BSA as the standard.
w 14 xAssays for oxidation of 1- C octanoic acid were
carried out using essentially the same procedure, with
60–80 mg proteinrtube. After the reactions were
 .terminated, chloroformrmethanol 2r1, vrv was
added to the reaction mixture to form two phases.
 .The aqueous phases 0.4 ml were extracted twice
with 1.33 ml of n-hexane. This has been demon-
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w 14 xstrated to remove )98% of 1- C octanoic acid
w xwithout removing ketone bodies or other WSP 3,22 .
Aliquots of the aqueous phases were counted for
14C-WSP.
2.4. Quantitation of hepatic CoA and CoA esters
At select times during the experiment, 4 to 6 mice
from each experimental group were killed by decapi-
tation and the livers were frozen immediately in
liquid nitrogen. At the time of sampling, portions of
the livers were weighed and homogenized in 0.6 N
PCA. The mixtures were centrifuged, and the super-
natants transferred to a second set of tubes, adjusted
to pH 4 with 2 M KHCO , and analyzed for CoA and3
its esters using the enzyme cycling method described
w xby McDougal and Dargar 23 . This method is based
on the CoA-dependent disappearance of acetylphos-
 .phate AcP when tissue extracts are incubated with
 .phosphoacetyltransferase PTA; EC 2.3.1.8 . To
quantitate total free CoA plus acid-soluble CoA es-
ters, the supernatants were heated for 30 min at 608C
 .pH 9.6 in the presence of 6 mM dithiothreitol
 .DTT . After being readjusted to pH 4.5, aliquots
were incubated with arsenate buffer 120 mM, pH
. 7.8 , and recycling reagent 15 mM AcP q75 mgrml
.PTA . After 17–20 h, the tube contents were reacted
with hydroxylamine and FeCl , and the color product3
was quantitated spectrophotometrically. The relation-
ship between the amount of AcP remaining and CoA
 .plus ester concentration in the samples was deter-
mined by comparison with values obtained for a
parallel set of CoA standards.
Levels of free CoA and acetyl-CoA were deter-
mined indirectly by omitting the DTT treatment and
altering incubation conditions in such a way that
specific components were released from the tissue
extract and destroyed by oxidation by reaction with
0.3% H O and 12 mM CuSO . The remaining2 2 4
esters were then quantitated using the cycling reac-
tion described above. The sum of acetyl-CoA, ace-
toacetyl-CoA plus other PTA-reactive species were
determined using the cycling reaction after CoASH
and succinyl-CoA were oxidized following their se-
lective liberation by heating the samples at 858C for
15 min. Acetyl-CoA was then quantitated as its loss
 .upon heating the samples 858C, 15 min in the
 .presence of citrate synthase 5 mgrml; EC 4.1.3.7
and oxaloacetate. Succinyl-CoA was measured in
isolation after free CoA and all esters were converted
 .to CoASH 08C, 15 min, 40 mgrml PTA and oxi-
dized with the cycling reagent that was supplemented
with MgCl , GDP and succinic thiokinase EC2
.6.2.1.4 . Appropriate blanks were used for all of the
assays. Quantities of individual CoA species were
calculated by subtracting the amounts of other com-
ponents from the total amounts of CoA obtained in
the assays with DTT.
Quantitation of the levels of acid-insoluble long-
chain fatty acyl-CoA esters involved PCA precipi-
tates from the initial centrifugation being washed and
dispersed in 75 mM 2-methyl,2-amino,propan-1-ol
that contained 6 mM DTT. Mixture preparation in-
cluded adjusting the pH to 9.3, heating at 608C for 30
min, reacidification, and centrifugation. The super-
natant was treated with DTT and carried through the
cycling reaction as described above.
2.5. Measurement of fatty-acid: CoA ligase acti˝ities
The liver homogenates were assayed for fatty
acid:CoA ligase activity as described by Singh and
w xPoulos 24 , with minor modifications. The reaction
mixtures contained in a final volume of 0.2 ml of
 .modified Krebs-Henseleit buffer pH 8.0 : 0.2 mM
w 14 x w 14 x1- C palmitic or 1- C octanoic acid, 1 mM ATP,
2 mM DTT, 2 mM KCN, and where indicated, 0.05
mM CoA. Reactions were initiated by addition of
30–50 mg of protein when exogenous CoA was
present or 150–160 mg when it was omitted, and
were continued at 378C for 5 min. They were termi-
nated with 20 ml of 10 M HCl, and 1.5 ml of an
extraction mixture isopropanol:heptane:10 M HCl,
.40:10:1, by vol was added. The resulting two phases
were separated by the addition of 1.5 ml heptane and
1 ml water. Aqueous phases were washed twice with
2 ml of heptane and aliquots were counted to quanti-
w 14 xtate the amount of 1- C fatty acyl-CoA formed.
Blank values were obtained by mixing all reactants
and terminating the reaction at ts0.
2.6. Statistical analyses
The data represent means"SD of values obtained
from 3–6 different mice. They were analyzed using a
Student’s unpaired t-test with Bonfarroni correction
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for multiple testing. Differences were considered sig-
nificant when P-0.05.
3. Results
3.1. Mortality
In the surfactantrFluB mouse model of AHE,
mice infected with FluB, with or without pre-ex-
posure to Tox generally begin to die two days after
 .inoculation i.e., experimental days 15, 16 , and the
maximum number of deaths is established between
Days 18 and 21. On day 19 in a representative
w xexperiment 14 , the % mortality in the FluB and
ToxqFluB groups was 42% and 78%, respectively.
3.2. Effects of exogenous CoA on Tox androrFluB-
mediated alterations of hepaticb-oxidation
The first question that we addressed in investigat-
 .ing the mechanism s underlying the alterations in
hepatic b-oxidation in the mouse model i.e., en-
hancement by dermal Tox, inhibition by FluB infec-
.tion was whether these alterations were affected by
the availability of CoA. Parallel assays of b-oxida-
w 14 xtion of 1- C palmitic acid with and without exoge-
nous CoA were carried out with homogenates of
livers from mice at experimental days 12 MEM,
.  .Tox and 19 MEM, Tox, FluB, ToxqFluB . With-
out CoA added, the maximum oxidation rates with
this fatty acid were only about 5% of those when
 .CoA was present in the assay media Fig. 1 . Never-
w 14 xFig. 1. Effects of exogenous CoA on hepatic 1- C palmitic acid b-oxidation in vitro in the surfactantrvirus mouse model for acute
 .hepatic encephalopathy. A. Neonatal mice were painted on their abdomens daily for 12 days with either MEM or Toximul MP8 Tox .
On the final day of painting they were killed, and livers were homogenized immediately in 5 vol of Krebs-Henseleit buffer. The
w 14 xhomogenates were then assayed for 1- C palmitic acid b-oxidation in parallel, with or without exogenous CoA, as described in Section
 .2. B. After painting was discontinued, half of each of the MEM and Tox groups were inoculated with a sublethal dose LD of30
 .  .mouse-adapted human influenza B Lee virus FluB ; the remainder were given light anaesthesia only. 5 days after inoculation, livers
w 14 xfrom mice in each of the four treatment groups were assayed for 1- C palmitic acid b-oxidation, with parallel assays running with or
 .without exogenous CoA. The data are the mean"SD of values obtained with 3–6 mice. Significant differences P-0.05 are indicated
by different letters above the data bars.
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theless, the system was sufficiently sensitive to detect
the effects of the different treatment regimens in the
mice. The day 12 livers demonstrated that an appar-
w 14 xent stimulation of 1- C palmitate oxidation by Tox
painting was reversed with removal of exogenous
 . CoA from the assay tubes Fig. 1A . On day 19 Fig.
.1B , a Tox-induced inhibition of palmitate oxidation
was still evident in the absense of added CoA. Of
note was the observation that FluB infection resulted
in an ;20% inhibition of palmitate oxidation, re-
gardless of whether CoA was added to the assay.
However, in its absence, the potentiation of the FluB
effect by Tox )80% inhibition, relative to MEM
.controls was greater than the sum of the inhibitory
 .  .effects of Tox 19% or FluB 27% alone.
w 14 xThese experiments were repeated using 1- C oc-
tanoic acid as the substrate, since circulating levels of
this C fatty acid in serum of children with RS8
suggested that this could be the point during fatty-acid
b-oxidation at which the metabolic block would be
w xdiscriminatory 25 . The first observation was that
oxidation of octanoate was much less dependent on
exogenous CoA than was that of palmitate, as evi-
denced by the fact that oxidation rates were reduced
by only about 45% as opposed to 95% with palmi-
.tate when CoA was omitted from the in vitro assays
 .Fig. 2 . However, Tox-dependent decreases in oc-
 . tanoate oxidation at days 12 Fig. 2A and 19 Fig.
.2B only occurred in the absence of exogenous CoA.
As was the case with palmitate, FluB infection alone
inhibited octanoate oxidation by ;30%, in a CoA-
independent manner. Once again, Tox potentiation of
FluB-induced inhibition of octanoate oxidation was
most obvious when assays were carried out without
exogenous CoA; in this case, the inhibition in the
 .ToxqFluB group )75% was greater than the sum
of that with livers from animals treated with Tox
 .  .8% and FluB 30% alone.
3.3. Effects of Tox and FluB on hepatic CoA,
acetyl-CoA and fatty acyl-CoA le˝els
Fig. 3A demonstrates that neither exposure of the
mice to Tox for 12 days, their infection with FluB,
nor the combined treatment with ToxqFluB altered
hepatic total CoA levels. However, quantitation of
the amounts of CoASH in the livers indicated that
mice that had been painted with Tox for either 8 not
w 14 xFig. 2. Effects of exogenous CoA on hepatic 1- C octanoic acid
b-oxidation in vitro in the surfactantrvirus mouse model for
acute hepatic encephalopathy. A. Octanoate b-oxidation at day
12 in MEM- and Tox-treated mice, with or without exogenous
CoA in the in vitro assay. B. Octanoate b-oxidation at day 19 in
MEM-, Tox-, FluB- and ToxqFluB-treated mice, with or with-
out exogenous CoA in the in vitro assay. Experimental details are
in the legend for Fig. 1, or in Section 2. Data are the means"SD
of values obtained with 3–6 mice. Significant differences P -
.0.05 are indicated by different letters above the data bars.
.shown or 12 days had levels of free CoA that were
20% lower than those of age-matched controls Fig.
.3B . This Tox-dependent decrease persisted through
day 19 of the experiment, 6 days after cessation of
painting; a similar magnitude of reduction in CoASH
was seen in ToxqFluB-treated mice. This latter
observation was consistent with the fact that FluB
alone did not alter hepatic CoASH levels.
Although hepatic levels of total acid-soluble CoA
esters were unaffected by Tox, FluB or ToxqFluB
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 .treatments not shown , there were significant effects
 .on levels of acetyl-CoA Fig. 3C . As was seen for
CoASH, hepatic acetyl-CoA content was significantly
depressed after the mice had been painted for 12 days
with Tox; however, in the Tox alone group, this
effect was reversed by day 19. Interestingly, FluB
treatment alone significantly reduced acetyl-CoA rel-
ative to either MEM or Tox controls. A similar
degree of reduction was also evident in the Toxq
FluB group.
The only increases that were observed in hepatic
CoA were those of the acid-insoluble acyl-CoA esters
 .Fig. 3D . These are usually esters of long-chain fatty
acids such as palmitoyl-CoA, and could possibly
include insoluble esters of Tox metabolites. Tox and
FluB treatments independently resulted in significant
increases in levels of thisrthese metabolites relative
to age-matched controls. There was neither summa-
tion nor potentiation of this effect in the group given
ToxqFluB.
[ 14 ]3.4. Effects of ToxrFluB on hepatic 1- C fatty
acid:CoA ligase acti˝ities
Since Tox- andror FluB-induced changes in hep-
atic CoA could affect fatty-acid activation we deter-
mined the activities of fatty acid:CoA ligase with
w 14 x  . w 14 x 1- C palmitic Fig. 4A and 1- C octanoic Fig.
.4B acids with the mouse livers. None of the experi-
w 14 xmental treatments affected 1- C fatty acyl-CoA for-
 .  .  .  .Fig. 3. Alterations in hepatic levels of total CoA A , free CoA B , acetyl-CoA C and acid-insoluble CoA esters D in the mouse
 .model for AHE. Neonatal mice were painted on their abdomens daily for 12 days with either MEM or Toximul MP8 Tox . On the final
day of painting, 3–6 mice from each group were killed, and livers were frozen at y708C. Half of each of the remaining groups were
 .  .  .inoculated with a sublethal dose LD of mouse-adapted human influenza B Lee virus FluB and the remainder were given light30
anaesthesia only. Five days after inoculation, livers were taken and frozen. All samples were analyzed for free CoA and its derivatives
w xusing the enzyme cycling assay of McDougal and Dargar 23 . Data are the means"SD of values obtained from 3–6 mice.
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Fig. 4. Effects of Tox, FluB, and ToxqFluB treatment on
w 14 x  . w 14 x  .activation of 1- C palmitic A and 1- C octanoic B acids.
Mice were carried through the ToxrFluB model as described in
Section 2, and in the legend to Fig. 1. The activities of fatty
acid:CoA ligase were determined essentially as described by
w xSingh and Poulos 24 , in the absence or presence of exogenous
CoA, as indicated. Data are the mean"SD of values obtained
from 3–6 mouse livers.
mation when exogenous CoA was included in the
assay media. Several features were apparent when
CoA was omitted. First, the activation rates in livers
of control mice were significantly lower with palmi-
tate than with octanoate. At day 12, activation of both
fatty acids was significantly reduced in Tox-painted
 .mice compared to controls MEM , and the extent of
 .inhibition ;35% was similar for both fatty acids.
By day 19, this effect appeared to be reversing, as the
;10% inhibitions were not significantly different
from values with the MEM controls or FluB-treated
mice. Fatty acyl-CoA formation was not affected by
FluB infection alone.
4. Discussion
This is the first report that b-oxidation is inhibited,
and CoA metabolism is interrupted by dermal expo-
sure to a widely-used industrial surfactant that in the
past was considered to be a relatively inocuous com-
pound. Most of the xenobiotics that have been re-
cently shown to alter one or both events do so
w xfollowing ingestion of the agent 1 . Tox or one or
more of its derivatives penetrate the skin, as measur-
able quantities were recovered from livers of humans
that had been exposed to emulsifier-suspended pesti-
w xcide and in livers of our Tox-treated mice 26 .
Another unique feature of the study was that it
demonstrated potentially important effects on inter-
mediary metabolism of treatment with Tox or FluB.
w xWith few exceptions 27,28 , studies have not investi-
gated the combined effects of xenobiotics and viral or
bacterial infections. Our mouse model involves both,
since it has been used to mimic human RS, which is
 .very often G85% associated with a viral infection
w x29 .
Based on unusual hepatic acyl-CoA profiles,
Corkey et al. proposed that several mitochondrial
pathways, including fatty-acid b-oxidation, were im-
w xpaired in RS patients 30 . Our studies demonstrated
direct evidence that b-oxidation of both palmitic
 .  .Fig. 1 and octanoic Fig. 2 acids is inhibited by
either dermally exposing young mice to Tox or in-
fecting them with FluB. Exogenous CoA could not be
present in the in vitro assay to demonstrate the
former; however, potentiation of FluB-induced inhibi-
tion was independent of its presence. Based on these
observations, it was reasonable to assume that the
Tox-mediated changes in fatty-acid oxidation that we
w xreported recently 14 could involve effects on CoA
metabolism, since many xenobiotic hydrocarbons are
w xesterified with CoA in vivo 31 . The major compo-
nents of Tox are dodecylbenzene sulfonates and
nonylphenol ethoxylates of polyethylene glycol,
which are anionic and nonionic surfactants, respec-
tively. The former exist as branched chain 11–13
.  .carbon atoms or linear 8–9 carbon atoms hydrocar-
bons that can undergo oxidative degration in vivo to
the sulfonyl carboxylic acids that could be substrates
w xfor the ligase reaction 14,19,20 . The recent studies
of Freneux et al. suggested that another xenobiotic,
the 2-arylpropionate, ibuprofen, also altered hepatic
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w xCoA metabolism 17 . These authors observed that
reducing the amount of CoA in their incubations
from 50 to 2.5 mM resulted in a reversal of the
 .drug-dependent effect from stimulation 20% to in-
 .hibition 45% of palmitate b-oxidation. As in this
 . w 14study Fig. 2 , they found that b-oxidation of 1-
xC octanoic acid was much less sensitive to changes in
CoA availability, even in the presence of their in-
hibitory agent. It was interesting to note that their
rates of b-oxidation with both fatty acids were con-
siderably lower than those observed in this study, but
this may be due to the fact that they used adult mice.
The hypothesis that Tox exposure altered CoA
metabolism in the mouse model was supported by the
data obtained in quantitative analyses of hepatic CoA
 .species Fig. 3 . After 12 days of dermal painting,
 . levels of free CoA Fig. 3B and acetyl-CoA Fig.
.3C were significantly reduced relative to the MEM
controls, although those of total hepatic CoA were
 .unchanged Fig. 3A . This finding was different from
that in the rat aspirinqendotoxin model of Kil-
w xpatrick et al. 27 , as in the latter, CoA and acetyl-CoA
were unaffected by aspirin treatment alone. In an-
other model, injection of suckling mice with valproic
acid reduced hepatic levels of both free CoA and
w xacetyl-CoA 32 ; however, acid-soluble short- and
medium-chain acyl-CoA and total CoA levels were
also elevated significantly, and this was not seen in
Tox-treated mice. Kang et al. reported that levels of
these metabolites were also elevated in autopsy liver
w xsamples of children who had died of RS 33 . These
inconsistencies in the effects of different xenobiotics
and other contributing factors on CoA metabolism
may reflect different mechanisms of action, andror
different target sites within the cell.
In addition to its effects on CoA metabolism, it
was also possible that Tox metabolites in vivo could
influence the activity of fatty-acyl CoA ligase, the
 .enzyme s responsible for activating fatty acids to
their corresponding CoA esters. This was confirmed
wby analysis of the enzyme activity with 1-
14 x w 14 x  .C palmitic and 1- C octanoic acids Fig. 4 . Of
particular interest was the observation that Tox-de-
pendent inhibition of ligase activity was only evident
when assays were carried out in the absence of CoA.
This could explain the recently-reported absence of
effect on ligase activity of many b-oxidation-inhibit-
w xing agents 34 , since these investigators carried out
their assays in the presence of relatively high 0.6
.mM quantities of CoA. Whether the inhibitions ob-
served in this model were due to direct Tox-depen-
dent inhibition of enzyme activity, or to competition
for it by Tox, is not known at present. The difference
between the levels of ligase activity with palmitate
and octanoate that were obtained when the assays
were carried out in the absence of exogenous CoA
could be explained by the fact that they were done
using liver homogenates. Depletion of extramitochon-
drial CoA by Tox would reduce the activation of
palmitic acid selectively, as this reaction occurs at the
outer mitochondrial membrane. By contrast, oc-
tanoate activation does not depend upon cytosolic
CoA, as it can cross directly into the mitochondria
where medium-chain acid CoA ligase and an inde-
pendent, concentrated supply of CoA are available.
w x  .As discussed previously 14 , the mechanism s
whereby FluB, a respiratory virus, inhibits b-oxida-
ton is not known. Isolation of active virus from the
mouse livers has not been demonstrated, however, we
have evidence that with pre-exposure to Tox, non-in-
fective FluB genomic material does invade this nor-
 .mally non-target organ unpublished observations .
An alternative explanation which could account for
inhibition of fatty acid oxidation in mice that were
only infected with FluB is that the virus could pro-
w xduce metabolites, including cytokines 35 , that could
inhibit enzyme activities, either directly or through
reduced enzyme synthesis, at targets distant from the
site of infection. Presumably the 27–30% inhibition
 .  .of palmitate Fig. 1 and octanoate Fig. 2 oxidation
in mice inoculated with FluB alone is directly associ-
ated with the 33% reduction in acetyl-CoA levels
 .Fig. 3C and the approximate 22% increase in acid-
 .insoluble acyl-CoA esters Fig. 3D in this model.
The only biochemical correlate of Tox potentiation
of FluB-induced mortality in our mouse model is the
potentiation by Tox of hepatic FluB-dependent inhi-
 .bition of b-oxidation Fig. 1B, Fig. 2B . This investi-
gation of the effects of the different treatment regi-
mens on levels of hepatic CoA and its metabolites
and of the activity of fatty acyl-CoA ligase did not
reveal any other specific aspects of cell metabolism
in which abnormalities were potentiated when mice
were given combined treatment with Tox and FluB.
Each of these insults alone has significant effects on
cellular metabolism; however, the precise basis for
( )M.G. Murphy et al.rBiochimica et Biophysica Acta 1361 1997 103–113112
the synergism seen in inhibition of b-oxidation and
mortality remains unidentified.
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